These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29061982)

  • 41. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
    Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
    Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
    J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.
    Lin YW; Ren LL; Xiong H; Du W; Yu YN; Sun TT; Weng YR; Wang ZH; Wang JL; Wang YC; Cui Y; Sun DF; Han ZG; Shen N; Zou W; Xu J; Chen HY; Cao W; Hong J; Fang JY
    J Pathol; 2013 Jul; 230(3):277-90. PubMed ID: 23424038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.
    Fornaro L; Faviana P; De Gregorio V; Vivaldi C; Paolicchi E; Masi G; Loupakis F; Sensi E; Lupi C; Fontanini G; Wang Y; Danesi R; Falcone A; Crea F
    BMC Cancer; 2015 Nov; 15():874. PubMed ID: 26553291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of C9orf140 in the promotion of colorectal cancer progression and mechanisms of its upregulation via activation of STAT5, β-catenin and EZH2.
    Weng YR; Yu YN; Ren LL; Cui Y; Lu YY; Chen HY; Ma X; Qin WX; Cao W; Hong J; Fang JY
    Carcinogenesis; 2014 Jun; 35(6):1389-98. PubMed ID: 24608043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
    Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
    PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma.
    Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W
    Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NBPF4 mitigates progression in colorectal cancer through the regulation of EZH2-associated ETFA.
    Chen W; Di Z; Chen Z; Nan K; Gu J; Ge F; Liu J; Zhang H; Miao C
    J Cell Mol Med; 2021 Sep; 25(18):9038-9050. PubMed ID: 34405537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
    Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
    Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 52. O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit.
    Jiang M; Xu B; Li X; Shang Y; Chu Y; Wang W; Chen D; Wu N; Hu S; Zhang S; Li M; Wu K; Yang X; Liang J; Nie Y; Fan D
    Oncogene; 2019 Jan; 38(3):301-316. PubMed ID: 30093632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis.
    Liu Y; Liu T; Bao X; He M; Li L; Yang X
    Int J Gynecol Pathol; 2014 May; 33(3):218-24. PubMed ID: 24681730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EZH2 promotes invasion and tumour glycolysis by regulating STAT3 and FoxO1 signalling in human OSCC cells.
    Zheng M; Cao MX; Luo XJ; Li L; Wang K; Wang SS; Wang HF; Tang YJ; Tang YL; Liang XH
    J Cell Mol Med; 2019 Oct; 23(10):6942-6954. PubMed ID: 31368152
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
    Abdel Raouf SM; Ibrahim TR; Abdelaziz LA; Farid MI; Mohamed SY
    J Gastrointest Cancer; 2021 Mar; 52(1):90-98. PubMed ID: 31823218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MicroRNA-506-3p inhibits colorectal cancer cell proliferation through targeting enhancer of zeste homologue 2.
    Ai L; Luo X; Yan X; Jiang S
    Bioengineered; 2021 Dec; 12(1):4044-4053. PubMed ID: 34288823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer.
    Ishikawa S; Hayashi H; Kinoshita K; Abe M; Kuroki H; Tokunaga R; Tomiyasu S; Tanaka H; Sugita H; Arita T; Yagi Y; Watanabe M; Hirota M; Baba H
    Int J Cancer; 2014 Dec; 135(11):2528-36. PubMed ID: 24346863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
    Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
    World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.